Liquidia Technologies Settles Patent Disputes with United Therapeutics for $380.7 Million, Ensuring Continued Distribution of Yutrepia
Liquidia Technologies, a biopharmaceutical company, has agreed to settle six lawsuits with United Therapeutics Corporation for a total of $380.7 million. This settlement resolves ongoing legal battles concerning the patent rights of the Yutrepia treatment, a key therapy for pulmonary arterial hypertension, affirming Liquidia’s access to continue its distribution. As highlighted by Law360’s coverage, the…